WHAT IS CLAIMED IS:

1. A compound having a formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein,

each of R^1 and R^2 is, independently, H, substituted or unsubstituted C_{1-6} alkyl, or substituted or unsubstituted C_{1-6} alkoxy, wherein the substituents are selected from the group consisting of hydroxy and halo;

R^3 is H, formyl, acetyl, or substituted or unsubstituted C_{1-3} alkyl, wherein the substituents are selected from the group consisting of hydroxy and halo;

each of R^4-R^8 is, independently, H, halo, substituted or unsubstituted C_{1-12} alkyl, substituted or unsubstituted C_{2-12} alkenyl, substituted or unsubstituted C_{2-12} alkynyl, substituted or unsubstituted C_{1-6} alkoxy, substituted or unsubstituted C_{2-12} alkenyloxy, substituted or unsubstituted C_{5-10} cycloalkenyloxy, substituted or unsubstituted (C_{2-12} alkynyl)oxy, (C_{1-6} alkyl)oxy(C_{1-6} alkyl), substituted or unsubstituted C_{6-12} aryloxy, (C_{3-6} heteroaryl)-(C_{1-6} alkyl)oxy, (C_{1-12} alkyl)thio, substituted or unsubstituted (C_{1-4} alkyl)-thio-(C_{1-4} alkyl), substituted or unsubstituted C_6-C_{10} aryl, substituted or unsubstituted styryl, substituted or unsubstituted C_{3-12} heteroaryl, substituted or unsubstituted C_{4-8} heterocyclic, -NH-C(O)-NH-(substituted or unsubstituted heteroaryl), or $-NR^{19}R^{20}$, wherein each of R^{19} and R^{20} is, independently, H, C_{1-12} alkyl, or C_{2-12} alkenyl, wherein the substituents are selected from the group consisting of hydroxy, halo, C_{1-4} alkyl, C_{1-4} trihaloalkyl, C_{1-6} alkoxy, C_{1-4} trihaloalkoxy, bivalent oxyalkyloxy, acylamino, acylthio, amino, and azido; or R^5 and R^6

form a C_5-C_{10} heteroaryl ring, and each of R^4, R^7, and R^8 is, independently, hydroxy, halo, C_{1-4} alkyl, C_{1-4} trihaloalkyl, C_{1-6} alkoxy, or C_{1-4} trihaloalkoxy;

provided that at least one of R^4-R^8 is not H; further provided that when R^1 is alkyl, then R^6 is not butyl; further provided that when R^1 is methyl and R^2 is H, then R^6 is not -C≡CH, -$NHCH_3$, CF_3, or $-CH_2CH_3$.

2. The compound of claim 1, wherein R^1 is C_1-C_4 alkyl.

3. The compound of claim 1, wherein R^1 is CH_3.

4. The compound of claim 1, wherein R^4, R^5, R^7, and R^8 are H.

5. The compound of claim 1, wherein R^3 is H.

6. The compound of claim 1, wherein R^6 is C_1-C_{10} alkyl.

7. The compound of claim 6, wherein R^6 is cyclopentyl.

8. The compound of claim 6, wherein R^6 is norbornyl.

9. The compound of claim 1, wherein R^6 is C_1-C_{10} alkoxy.

10. The compound of claim 1, wherein R^6 is substituted or unsubstituted C_6-C_{10} aryl.

11. The compound of claim 1, wherein R^6 is substitutedor unsubstituted C_2-C_{12} alkenyl.

12. The compound of claim 1, wherein each of R^4-R^8 is, independently, H, halo, substituted or unsubstituted C_{1-12} alkyl, substituted or unsubstituted C_{2-12} alkenyl, substituted or unsubstituted C_{2-12} alkynyl, substituted or unsubstituted C_{1-6} alkoxy, substituted or

unsubstituted phenyl, substituted or unsubstituted heteroaryl, or -NH-(C_{1-6} alkyl), wherein the substituents are selected from the group consisting of hydroxy, halo, and C_{1-4} alkyl.

13. The compound of claim 12, wherein R^4, R^5, R^7, and R^8 are H.

14. The compound of claim 12, provided that when R^1 is alkyl, then R^6 is not alkyl.

15. The compound of claim 12, provided that when R^1 is methyl and R^2 is H, then R^6 is not alkyl.

16. The compound of claim 12, provided that when R^1 is methyl and R^2 is H, then R^6 is not alkynyl.

17. The compound of claim 12, provided that when R^1 is methyl and R^2 is H, then R^6 is not -NH(C1-C6 alkyl).

18. The compound of claim 12, wherein R^3 is H.

19. A pharmaceutical composition comprising a compound of Formula (I) of claim 1 and a pharmaceutically acceptable carrier.

20. The composition of claim 19, wherein the compound is a compound of claim 2.

21. The composition of claim 19, wherein the compound is a compound of claim 4.

22. The composition of claim 19, wherein the compound is a compound of claim 5.

23. The composition of claim 19, wherein the compound is a compound of claim 6.

24. The composition of claim 19, wherein the compound is a compound of claim 9.

25. The composition of claim 19, wherein the compound is a compound of claim 10.

26. The composition of claim 19, wherein the compound is a compound of claim 12.

27. A method of treating a fungal infection in a subject identified as in need of such treatment comprising administering an effective amount of a compound of Formula (I) in claim 1 to the subject.

28. A method of treating a fungal infection in a subject identified as in need of such treatment comprising administering an effective amount of a pharmaceutical composition of claim 19 to the subject.

29. A compound having a formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein

each of R^{21} and R^{22} is, independently, substituted or unsubstituted C_{1-6} alkyl, or substituted or unsubstituted C_{1-6} alkoxy, wherein the substituents are selected from the group consisting of hydroxy and halo;

R^{23} is substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{6-12} aryl, substituted or unsubstituted C_{3-12} heteroaryl, wherein the substituents are selected from the group consisting of halo, C_{1-6} alkyl, and C_{1-6} trihaloalkyl.

30. The compound of claim 29, wherein R^{21} is C_1-C_4 alkyl.

31. The compound of claim 29, wherein R^{21} is CH_3.

32. A pharmaceutical composition comprising a compound of Formula (II) of claim 29 and a pharmaceutically acceptable carrier.

33. A method of treating a fungal infection in a subject identified as in need of such treatment comprising administering an effective amount of a compound of Formula (II) in claim 29 to the subject.

34. A method of treating a fungal infection in a subject identified as in need of such treatment comprising administering an effective amount of a pharmaceutical composition of claim 32 to the subject.

35. A method of treating a fungal infection in a subject identified as in need of such treatment comprising administering a compound of Formula (I) in claim 1 to the subject in combination with a second antimicrobial agent .

36. A composition comprising a compound of Formula (I) in claim 1 and a second antimicrobial agent.

37. A method of treating a fungal infection in a subject identified as in need of such treatment comprising administering a compound of Formula (II) in claim 29 to the subject in combination with a second antimicrobial agent .

38. A composition comprising a compound of Formula (II) in claim 29 and a second antimicrobial agent.

39. A composition according to claim 36 or 38, wherein the second antimicrobial agent is selected from the group consisting of polyenes, candins, sordarins, azoles, allylamines, and morpholines.

40. The method according to claim 35 or 37, wherein the second antimicrobial agent is selected from the group consisting of polyenes, candins, sordarins, azoles, allylamines, and morpholines.